There are 2949 resources available
460P - Update analysis of phase II study of oxaliplatin based regimen in relapsed colorectal cancer patients treated with oxaliplatin based adjuvant chemotherapy: INSPIRE study
Presenter: Hironaga Satake
Session: E-Poster Display
Resources:
Abstract
461P - Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience
Presenter: Pietro Paolo Vitiello
Session: E-Poster Display
Resources:
Abstract
462P - Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States
Presenter: Christopher Nevala-Plagemann
Session: E-Poster Display
Resources:
Abstract
463P - The prognostic role of tumour inflammation markers in patients (pts) with colorectal cancer (CRC) treated with trifluridine/tipiuracil hydrochloride: Real-world data (RWD) from Greater Manchester
Presenter: Alia Alchawaf
Session: E-Poster Display
Resources:
Abstract
464P - Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)
Presenter: Janet Graham
Session: E-Poster Display
Resources:
Abstract
465P - Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial
Presenter: Francesca Battaglin
Session: E-Poster Display
Resources:
Abstract
466P - FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Mikhail Fedyanin
Session: E-Poster Display
Resources:
Abstract
468P - PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC)
Presenter: Kathleen Janssens
Session: E-Poster Display
Resources:
Abstract
469P - Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
Presenter: Kefeng Ding
Session: E-Poster Display
Resources:
Abstract
470P - Anti-tumor mechanisms of rigosertib in colorectal cancer
Presenter: Seyed Mahdi Hassanian Mehr
Session: E-Poster Display
Resources:
Abstract